Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Breakthrough in ALS Lung Function, Survival Through NP001 Platform
Details : NP001 is an HSP90 inhibitor small molecule drug candidate which is currently being evaluated for the treatment of patients with amyotrophic lateral sclerosis.
Brand Name : NP001
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 16, 2024
Neuvivo Seeks FDA Approval for Its Breakthrough ALS Treatment NP001
Details : NP001 is an investigational product (sodium chlorite), which is being investigated in the late-stage clinical trial for the treatment of amyotrophic lateral sclerosis.
Brand Name : NP001
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 07, 2024
Neuvivo Raises $11M in Venture Financing to Develop Treatment for ALS
Details : The financing will be used for the continued development of NP001, a novel regulator of inflammatory macrophages and monocytes, for the treatment of ALS.
Brand Name : NP001
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 15, 2023
Details : NP001, is a small molecule which, through a series of biochemical interactions in the body, is converted to a compound that can transform inflammatory macrophages (M1) to the non-inflammatory, wound healing state (M2), with the goal of stopping damage to...
Brand Name : NP001
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 01, 2022
Neuvivo Begins Manufacturing of NP001 for Treatment of ALS
Details : NP001 has been shown to be effective and safe in clinical trials. Published data show a 38% slowing of disease progression as measured by ALSFRS-R score and importantly, a 51% slowing of the decline in lung function compared to placebo.
Brand Name : NP001
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 11, 2022
LOOKING FOR A SUPPLIER?